You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 3, 2024

CLINICAL TRIALS PROFILE FOR DANYELZA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for DANYELZA

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05489887 ↗	Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma	Not yet recruiting	Wake Forest University Health Sciences	Phase 2	2022-08-01	This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. Subjects with an ALK mutation or amplification will have ceritinib added to their treatment regimen as soon as results are available. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for DANYELZA

Condition Name

Chart
Table

Condition Name for DANYELZA
Intervention	Trials
High-risk Neuroblastoma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for DANYELZA
Intervention	Trials
Neuroblastoma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for DANYELZA

Trials by Country

Map
Table

Trials by Country for DANYELZA
Location	Trials
United States	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for DANYELZA
Location	Trials
North Carolina	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for DANYELZA

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for DANYELZA
Clinical Trial Phase	Trials
Phase 2	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for DANYELZA
Clinical Trial Phase	Trials
Not yet recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DANYELZA

Sponsor Name

Chart
Table

Sponsor Name for DANYELZA
Sponsor	Trials
Wake Forest University Health Sciences	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for DANYELZA
Sponsor	Trials
Other	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.